| |
Scientific innovation in ligand targeting has spurred the development of many different types of radiopharmaceuticals (RPs) with a wide range of clinical uses. As those uses have grown, developers of RP products are faced with a regulatory environment that can be a challenge to navigate. We have a roadmap – read our guide for the details. Learn more. Premier Research. Built for Biotech℠ 
|
|
Today’s Big NewsNov 6, 2023 |
| By Annalee Armstrong Another day, another antibody-drug conjugate deal. This time it’s Bristol Myers Squibb snapping up Orum Therapeutics’ phase 1 blood cancer med for $100 million upfront. |
|
|
|
By Max Bayer BioNTech is spending more of its COVID cash, betting over $1 billion on a licensing deal for a phase 2 bispecific antibody, just days after closing the acquisition of a lipid nanoparticle startup. |
By Helen Floersh Academics and industry folks from around the cancer world convened in sunny San Diego Nov. 1-5 at the Society for Immunotherapy of Cancer’s annual conference. Here are a few preclinical highlights. |
Sponsored by Resilience US, Inc. Digital twins can help biomanufacturing organizations spot and avoid failures that lead to costly delays. Explore this article to find out how. |
By James Waldron Kodiak Sciences gave up on tarcocimab tedromer earlier this year after a pair of phase 3 trials ended in failure. But a fresh batch of late-stage data has now given the anti-VEGF drug another shot at approval. |
By James Waldron MoonLake Immunotherapeutics has maintained its position as a key player in the race to get an IL-17 inhibitor to market for inflammatory skin conditions courtesy of another successful phase 2 readout. |
By Annalee Armstrong Celldex Therapeutics has some huge competition in immunology, but new phase 2 data from its monoclonal antibody showing a reduction in the severity of a chronic form of hives is helping put the biotech in the game. |
By Helen Floersh Two new studies offer more validation that prime editing and base editing have potential efficacy against the rare disease phenylketonuria. |
By Eric Sagonowsky Astellas is counting on Izervay to deliver gains in a heated GA market clash against rival Apellis. Now, 2-year data show the drug's effects increase over time. |
By Conor Hale BD is building on its goal of providing patients with a “one-stick hospital stay,” with a new FDA clearance for painless blood collection hardware that works through already placed IV lines. |
By Fraiser Kansteiner As shortages of drugs like amoxicillin, penicillin, Adderall and certain chemotherapies continue to confound doctors and patients in the U.S., two high-ranking Republican lawmakers are pressing the FDA for answers. |
By Andrea Park People suffering from chronic insomnia now have a new, drug-free option to treat the condition in the U.S. |
By Noah Tong Medicare Advantage prior authorization denials are in the crosshairs of House Democrats. They say evidence points toward insurers willingly allowing algorithms to wrongfully deny service to patients. |
Fierce podcasts Don’t miss an episode |
| While the new Alzheimer’s disease medicine Leqembi has generated lots of buzz since its debut this year, one research team is investigating whether the medicine holds promise in preventing disease progression before any Alzheimer’s symptoms are evident. In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky talks with the study lead, Reisa Sperling, M.D., to learn more. |
|
|---|
|
|
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
Whitepaper This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Edison Ballroom, New York City |
|
|
| |
|
